Jeffrey Rubinstein
Interventional Cardiology · Lakewood, CONPI 1417953399
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (55.9%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by W. L. Gore & Associates, Inc. at 38.9% of the total. Reporting peaked in 2020 at $8,019 and has fallen 88.5% since, to $921 in 2025.
Across 269 payments — averaging $82.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- W. L. Gore & Associates, Inc.$9K
- Abbott$3K
- Medtronic$2K
- Shockwave Medical, Inc$2K
- Boston Scientific$2K
- Philips North America LLC$2K
- plus $2K from 23 others
What the payments were for
- Speaking & faculty fees$6,48029%
- Travel & lodging$3,29515%
- Food & beverage$12,39556%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| W. L. Gore & Associates, Inc. | 44 | $8,623 |
| Abbott | 30 | $2,695 |
| Medtronic(2 entities) | 31 | $2,351 |
| Shockwave Medical, Inc | 22 | $2,205 |
| Boston Scientific | 29 | $2,080 |
| Philips North America LLC | 33 | $1,789 |
| Abiomed | 5 | $547 |
| Edwards Lifesciences | 2 | $314 |
| Merck | 10 | $230 |
| Pfizer | 10 | $226 |
| Johnson & Johnson | 9 | $180 |
| Sanofi-aventis U.S. LLC | 7 | $167 |
| Novartis | 6 | $122 |
| Cardiovascular Systems Inc. | 7 | $99 |
| E.r. Squibb & Sons, L.L.C. | 3 | $70 |
| Cardiva Medical, Inc. | 2 | $64 |
| Bard Peripheral Vascular, Inc. | 1 | $56 |
| Esperion Therapeutics, Inc. | 3 | $47 |
| Bayer | 2 | $40 |
| Novo Nordisk | 2 | $40 |
| Asahi Intecc USA, Inc. | 1 | $38 |
| Amgen | 2 | $36 |
| Heartflow, Inc. | 2 | $34 |
| Impulse Dynamics (USA) Inc. | 1 | $26 |
| Baxter Healthcare | 1 | $25 |
| Lexicon Pharmaceuticals, Inc. | 1 | $22 |
| GE HealthCare | 1 | $22 |
| Scpharmaceuticals Inc. | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CARDIOFORM Septal Occluder$7,902
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$1,556
- Resolute$1,409
- Xience V coronary stent system$773
- GENERAL - THERAPIES$573
- AVVIGO Guidance System$448
- Impella$433
- MitraClip$378
- IGT D Coronary$243
- (9520) IGT Devices Undivided$224
- Spectranetics Undiv$215
- Vascular Lithotripsy$174
- WATCHMAN Access System$157
- Reveal LINQ$155
- Xience Sierra Coronary Stent System$146
- GORE CARDIOFORM Septal Occluder$143
- GORE CARDIOFORM ASD Occluder$141
- Diamondback Coronary$134
- (6371) Laser CVX300$125
- Euphora$119
How this compares
$22,179 in reported general payments places this provider in the 70th percentile of 111 interventional cardiology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 294 | $351,290 |
| XareltoRivaroxaban | 169 | $226,288 |
| Repatha SureclickEvolocumab | 105 | $104,240 |
| JardianceEmpagliflozin | 33 | $57,905 |
| EntrestoSacubitril/Valsartan | 25 | $43,651 |
| Praluent PenAlirocumab | 26 | $27,118 |
| MultaqDronedarone Hcl | 14 | $19,618 |
| BrilintaTicagrelor | 18 | $15,081 |
| Metoprolol Succinate | 488 | $5,925 |
| Atorvastatin Calcium | 516 | $4,606 |
| Losartan Potassium | 396 | $3,985 |
| Rosuvastatin Calcium | 245 | $3,107 |
| Prasugrel Hcl | 23 | $2,131 |
| Spironolactone-HctzSpironolact/Hydrochlorothiazid | 38 | $1,856 |
| Potassium Chloride | 128 | $1,832 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $226 | $351,290294 claims |
| Johnson & JohnsonXarelto | $180 | $226,288169 claims |
| NovartisEntresto | $122 | $43,65125 claims |
| Sanofi-aventis U.S. LLCMultaq | $167 | $19,61814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 111 interventional cardiology providers in Colorado.
Other interventional cardiology in Lakewood
- Nima AghiliLakewood$220K
- Ashwin MurthyLakewood$17K
- Ahmad AlqaqaLakewood$15K
- Ehrin ArmstrongEnglewood$718K
- Gareth MorganAurora$536K
- Jamaluddin MolooAurora$272K
- Jenny Zablah AlabiAurora$269K
- Srinivas IyengarBoulder$254K
- Sridhar Sampath-KumarAurora$142K
- Matthew ZipseAurora$137K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.